Autres langues Harrow, Inc.

Actions

HROW

US4158581094

Marché Fermé - OTC Markets Autres places de cotation 22:00:00 26/04/2024			Varia. 5j.	Varia. 1 janv.
10,53 ^USD	+5,30 %		+0,77 %	-5,98 %

11/04	HARROW, INC. : Craig-Hallum optimiste sur le dossier	ZM
22/03	HARROW, INC. : B. Riley maintient sa recommandation à l'achat	ZM

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Harrow Will Release First Quarter 2024 Financial Results After Market Close on May 13, 2024	26/04
Melt Pharmaceuticals Closes $24 Million Series B Preferred Stock Financing	03/04
Top Midday Decliners	20/03
Harrow Announces Fourth Quarter and Year-End 2023 Financial Results	20/03
Harrow, Inc. Provides Earnings Guidance for the Year 2024	20/03
Harrow Health Slumps 13% Premarket After Swinging to Core Net Loss in Q4 While Sales Jumped	20/03
North American Morning Briefing : Markets on Hold as Fed Decision Nears	20/03
Harrow : Q4-2023 Letter to Stockholders	19/03
Harrow, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	19/03
Harrow, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	19/03
Restore stock falls as weak tech trading drags down annual results	14/03
Harrow Will Release Fourth Quarter and Year-End 2023 Financial Results after Market Close on March 19, 2024	06/03
Harrow Announces New Appointments to its Board of Directors	30/01
Harrow, Inc. Announces Board of Director Appointments	29/01
Harrow Announces Availability of VEVYE 0.1%, the First and Only Cyclosporine-Based Product Indicated for Treating Both Signs and Symptoms of Dry Eye Disease	12/01
Harrow Health's Eye Treatment Drug Vevye Now Available in US	11/01
Harrow Announces Availability of Vevye® (Cyclosporine Ophthalmic Solution) 0.1%, the First and Only Cyclosporine-Based Product Indicated for Treating Both Signs and Symptoms of Dry Eye Disease	11/01
Harrow Partners with Leading Healthcare Market Access Technology Platforms	04/01
Melt Pharmaceuticals Provides Corporate Update	04/01
Harrow, Inc. Partners with Leading Healthcare Market Access Technology Platforms	03/01

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Harrow, Inc.

Actions

HROW

US4158581094

Autres langues

Filtres